Phase II study of chlorozotocin in the treatment of advanced colorectal cancer.

Abstract

In 39 patients with advanced colorectal cancer and no previous chemotherapy, treatment with chlorozotocin was associated with a 5% objective response rate and a median survival of 19 weeks. All of the responses occurred in patients with rectal tumors. Mild gastrointestinal symptoms affected 64% of the patients after treatment, but bone marrow suppression was not evident. Chlorozotocin is not effective against colorectal cancer when used as a single agent given as an iv bolus at doses of 120 mg/m2 (30 patients) and 150 mg/m2 (nine patients). However, further studies using a higher dose might be worthwhile.

• Authors: J O Lawton, G R Giles, J Hall, A MacAdam, R Hall, T Matheson, G Bird
• Journal: Cancer treatment reports (Cancer Treat Rep) 1981 Jan-Feb Vol. 65 Issue 1-2 Pg. 13-15 ISSN: 0361-5960 [Print] United States
• PMID: 6452945 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• chlorozotocin
• Streptozocin

Topics

• Adenocarcinoma (drug therapy)
• Aged
• Antineoplastic Agents (therapeutic use)
• Colonic Neoplasms (drug therapy)
• Dose-Response Relationship, Drug
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Rectal Neoplasms (drug therapy)
• Streptozocin (analogs & derivatives, therapeutic use)